DIMPLE SAHNI

Dimple Sahni stands as a pivotal figure in the global health investment landscape, serving as a Partner at Adjuvant Capital. Adjuvant Capital is a unique venture fund dedicated to advancing innovative health technologies that address some of the world's most pressing health challenges, particularly in underserved populations. Sahni's role involves identifying, evaluating, and supporting groundbreaking companies developing vaccines, therapeutics, diagnostics, and medical devices with the potential for transformative global health impact.

Her investment philosophy is deeply rooted in the belief that financial returns and social impact can, and should, go hand in hand. Dimple Sahni champions a rigorous approach to impact investing, ensuring that Adjuvant Capital's portfolio companies not only demonstrate strong commercial viability but also promise significant public health benefits. Her focus areas are broad yet critical, encompassing infectious diseases like tuberculosis, malaria, and HIV, as well as maternal and child health, neglected tropical diseases, and other conditions disproportionately affecting low and middle-income countries.

Sahni's extensive career background has equipped her with a profound understanding of both the financial and public health sectors. Prior to her tenure at Adjuvant Capital, she held significant roles that honed her expertise in global health finance and impact investing. Her experience includes working with organizations dedicated to accelerating the development and delivery of health innovations for the poor, often involving complex partnerships between public, private, and philanthropic entities. This background provides her with a unique perspective on navigating the intricacies of drug development, market access, and sustainable business models in challenging environments.

At Adjuvant Capital, Dimple Sahni is instrumental in shaping the fund's strategy and executing its mission. She is actively involved in deal sourcing, due diligence, and portfolio management, working closely with entrepreneurs and scientific teams to bring life-saving innovations to fruition. While specific individual investments are often part of a broader fund strategy, her work contributes directly to Adjuvant Capital's track record of supporting companies that have developed novel solutions for diseases like dengue, cholera, and various bacterial infections, ultimately aiming to improve health outcomes for millions globally. Her leadership ensures that Adjuvant Capital remains at the forefront of impact-driven life sciences venture capital.